文献速递急性肾损伤肾小球疾病

补体因子B突变导致旁路途径液相失调引发非典型溶血性尿毒症综合征

Mutation of complement factor B causing massive fluid-phase dysregulation of the alternative complement pathway can result in atypical hemolytic uremic syndrome.
PubMed 文献 · Kidney Int · 2020-06-12

研究评估了两例非典型溶血性尿毒症综合征患者,均携带CFB新发杂合变异c.1101C>A(p.Ser367Arg),表现为C3不可测及C5和备解素降低。功能研究显示该变异为功能获得性致病突变,导致旁路途径液相失调和细胞表面C3b沉积增加,增加因子H浓度可恢复C3转化酶活性控制。

要点

  • CFB p.Ser367Arg是功能获得性致病变异,导致旁路途径液相失调。
  • 患者表现为C3不可测及、C5和备解素降低,提示旁路和终末途径过度活化。
  • 增加因子H浓度可在体外恢复C3转化酶活性控制。

核心结论

  • CFB p.Ser367Arg是功能获得性致病变异,导致旁路途径液相失调和细胞表面C3b沉积增加,可引发非典型溶血性尿毒症综合征。

研究设计与样本

  • 研究评估了两例无亲缘关系的非典型溶血性尿毒症综合征患者,并进行功能研究。

主要发现

  • 两例患者均携带CFB杂合变异c.1101C>A(p.Ser367Arg),C3水平不可测及,C5和备解素水平降低。
  • 混合正常血清和先证者血清时出现强液相C3裂解,患者血清补充C3后细胞表面C3b沉积强阳性。
  • 增加因子H浓度可在体外恢复C3转化酶活性控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atypical hemolytic uremic syndrome is an ultra-rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia and acute kidney injury. Its pathogenesis is driven most frequently by dysregulated cell-surface control of the alternative pathway of complement secondary to inherited and/or acquired factors. Here we evaluated two unrelated patients with atypical hemolytic uremic syndrome. The first, a five-year-old Caucasian female, presented at 10 months with schistocytes, thrombocytopenia and kidney injury. The second, a 55-year-old Caucasian female, presented at age 31 following caesarean section for preeclampsia. Complement biomarker testing was remarkable for undetectable levels of C3 in both. Circulating levels of C5 and properdin were also low consistent with over-activity of the alternative and terminal pathways of complement. Genetic testing identified a heterozygous novel variant in CFB (c.1101 C>A, p.Ser367Arg) in both patients. Functional studies found strong fluid-phase C3 cleavage when normal and proband sera were mixed. Cell-surface C3b deposition was strongly positive when patient serum was supplemented with C3. In vitro control of C3 convertase activity could be restored with increased concentrations of factor H. Thus, CFB p.Ser367Arg is a gain-of-function pathogenic variant that leads to dysregulation of the alternative pathway in the fluid-phase and increased C3b deposition on cell surfaces. Our study highlights the complexities of complement-mediated diseases like atypical hemolytic uremic syndrome and illustrates the importance of functional studies at the variant level to gain insight into the disease phenotype.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Kremsdorf RA, Sperati CJ, et al. Mutation of complement factor B causing massive fluid-phase dysregulation of the alternative complement pathway can result in atypical hemolytic uremic syndrome. Kidney Int. 2020. PMID: 32540405. doi:10.1016/j.kint.2020.05.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。